Paula, Thank time you you call appreciate joining for We especially you, this afternoon. in, time and this pandemic. thank listening the coronavirus during the the taking everyone to of unprecedented
We in our in XXXX. improvements achieved significant operational performance have
cash we XXXX, two has decreased XXXX. as to XXXX And XX% to compared and increased positive flow XX% by profit indicated adjusted net revenue EBITDA XXXX. compared Our operational XXX% of increased expenses quarters as gross compared to achieved in
to therapy the for Therapeutics from new gene of last During XXXX, and Xst tools ThermoGenesis leading-provider its transformation company ThermoGenesis corporate cell in aimed the emerging Holdings, focus, the changed name by of cell processing taking we better steps, November and continued To becoming a number year, Inc. reflect Cesca on at of the field. services our
and processing cells that has and store isolate, systems automated brand stem blood ThermoGenesis for well-recognized XXs, a the hematopoietic industry. been cord purify cryogenically a the bank for pioneer Since cell
large leveraged banking, and on scale to develop now and position stem point-of-care therapies. for that automated cell devices cell, cell technologies commercialize for therapies. and immunotherapy medical a This drugs range includes applications full stepped CAR-T of cell We manufacturing gene and have
a As we global milestone discussed our on XXXX in the cutting distribution achieved platform. signing of X-Series a Corning products, part last with we technology CAR-TXpress with edge for agreement major commercialization have which is our call, of
agreement, of and upfront to from ThermoGenesis Corning. million distribution future the a fees marketing part receive will received $X continue As support
We the and research expect of global products the market. distribution this agreement to awareness expand sales through X-Series
Outsourcing additional for to allow such the sales channel also point-of-care X-Series global the to services with will as greater of and marketing gene tools products maintain and a therapy cell, us company established well Corning developing on and a the focus sales markets.
in a Another form immune cell important agreement venture the the to ImmuneCyte, bank U.S. of XXXX is USA with first advancement cGMP which was HealthBanks the Biotech compliant execution in joint
to processing own as purchase with cell CDMO ImmuneCyte’s CAR-T from therapies cells use healthy peripheral future resource their to proprietary to as joint venture right for if is other for provide isolates banking. bank a ImmuneCyte or a has opportunity mandate for CMO immune cells XXX blood also cells immuno-therapies our and The platform services. cell CAR-TXpress XXX healthy of using CAR-TXpress needed. such cells the individuals automated immune non-exclusive ml for cell-based immune to pancreatic
and the investment of also of joint the $XX We a valuation from the has after The long establishment growth coming were prospects million investor ThermoGenesis’ venture in of pre-money million. joint potential the ImmuneCyte’s validates business implied received $X investments model venture. with pleased that this increases equity value the -- third-party ImmuneCyte investments an and not a important of private investor
we venture, our programs. of divested part As joint the ImmuneCyte clinical
with at the processing the cell, gene great positioning the now effort focused services. therapy and on products is and critical manufacturing and singularly company addressing this market ThermoGenesis of unmet result, need the cell a forefront of As
the On continue of completed the we were been among launch drive blood the new pleased launches. market-leading which original AXP of XXXX, with revenue II replace to our broadly device, important In commercial we have product generation end, which an has AXP banks next introduced top used enhancement we to cord product System worldwide.
the in System standards well have market. Since has AXP processing defined blood its cord the Since for introduction, by upgrades, the II industry. including the System innovative The significant AXP been the in received Group, Asia, its the II many leading introduction, are others upgraded CBR; and to banking blood bank, cord largest cord a of AXP System have Cordlife America's and blood provider both following. service
processing into We a we Center point-of-care step automated of the system physician agreement company's strategic which bone Method’s Orthohealing have of Canada forward is at PXP network important received the of point-of-care. PXP Management cells with provide System supply to approval our marrow for an market. the Subsequently, to also Health entered members, have for Orthohealing
currently cell platforms. As three a reminder, processing markets company the
technology sorting which The cell efficiency The large first cellular CAR-TXpress patent innovative B-A-C-S, lipids for key is to manufacturing intended one the BACS is cell high is the based CAR-TXpress technology is BACS, the scale protected sorting technology. platform need buoyancy-activated platform, BACS CAR-T technology unmet microbubbles. technology address therapies. a of or of a on component using critical
and platform cryostorage platform blood cord clinical clinical samples. automated second The the biobanking, is which of allows AXP/BioArchive for for and processing
the bone the automated cells blood or centers or PXP platform processing marrow And stem such locations, point-of-care platform allowing is for of autologous as applications, at point-of-care clinics. derived peripheral surgical the third
the closer alone take the market. of a therapy how market, therapies must This therapy exponential the of key global coming ThermoGenesis gene worldwide. cell to therapies address development cell, the and cell robust the more already cost. to challenges space a X,XXX product tabular revolutionary growth CAR-T in reasonable has to number gene of pending the grade the clinical and with has of developer commercial ongoing to line clinicaltrials.gov, trials cell in According drug advantage in positioned scale With manufacture surpassed at clinical
therapies. scale time obstacle presenting field. and can We well our large platform need cell, are widespread address this believe the use in technology manual revolutionary an CAR-TXpress gene processing methodologies consuming, to cell critical gene unmet Traditional cell, of still in therapy manufacturing
for cells also therapy. recent on that eligibility the not get or but the trials CAR-T CAR-T driving as therapy. several to to decay patients sufficient manufactured these during Factors with of shown patient the accessibility compromised XX% body's failed system be enrolled for XX% may have the is immune patients studies to eligible problems side, cancer as and that chemotherapy many enroll age On include and the of fact radiation severely clinical
production the of but body's source, contaminating only healthy Additionally, cases the in bloodstream, advanced also cancer of many T-cells. not cells with the the enter natural metastasize and cancer, interfering
this for venture, joint platform put will the cell for will address in later therapies. ImmuneCyte CAR-TXpress cell, to therapy market. helping through edge the issue healthy to manufacturing use shortcoming immune the cells at is cutting ImmuneCyte the offer people current gene the solving ThermoGenesis the bank of which processing cellular ability
summary, In and have undertaken are cell, and in last gene to provider therapy market. are the expected a revenue. launched we cellular products becoming ThermoGenesis manufacturing The strategic to focused tools continue on solution services drive changes for key to year
cash trend goal expect reduction of revenue in XXXX to flow the growth achieve continued positive continued see to we in year. growth our for entire of the and and costs, is With
pandemic XX,XXX. newest already what over year it regions, than has for The to over XX,XXX some United to development current XXXX, provide the coronavirus, has countries global have more want now company. cases of been I I on the of in and alone, increased including of affected by additional to actually summarized XXX COVID-XX, In the addition updates the and States today
societal threat. The The on disruption, has reagents a public disease develop impact spread U.S. to globally and tools leading take health health help and fight the could -- the U.S. and high, the both rapidly, wants by threat to that is social on posed system critical this company the to more in causing COVID-XX tremendous and healthcare global responsibilities extremely
at and venture together rapid effectively register, stressed burdening without to as at resources of technology the approval ImmuneCyte will the simple cases. kit its or working the routine ThermoGenesis conduct To The COVID-XX people that to and expertise, for field of in quick diabetic are diagnosis to glucose and at import U.S. virus, millions testing currently develop, do-it-yourself global be seek COVID-XX test self-test. point-of-care medical point-of-care quarantined would home, asymptomatic joint allow FDA as to a setting advanced already pandemic, tests A pregnancy their further be the done system. home both allow test, the able home approved, will the relationships tests including mobilizing healthcare respond or potentially if a
The such rapid ImmuneCyte. first second as available quarter through as early could test and point-of-care ThermoGenesis be of
We review FDA the expect for expedited an with file to process these tests. for
Jeff to key me XXXX. the the And Jeff? from with over let financial turn that, to results share call
